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Abstract
Background—Adverse events from inappropriate medications are preventable risk factors for
nursing home admissions.
Objective—We sought to investigate the relationship between inappropriate medications in older
adults and transitions to nursing home.
Methods—A retrospective cohort of Medicare beneficiaries with employer-sponsored
supplemental health insurance was analyzed using a longitudinal data set of Medicare
supplemental insurance claims. After a baseline year with no nursing home admissions, subjects
were followed until the first month of transition to nursing home, loss to follow-up, or the end of
the 24-month follow-up period. Survival analysis was used to compare the risk of nursing home
transition among those with and without inappropriate drug use in the previous 3 months.
Results—Of the 487,383 subjects in the cohort, 22,042 (4.5%) had a nursing home admission.
Use of inappropriate drugs was associated with a 31% increase in risk of nursing home admission,
compared with no use of inappropriate drugs (adjusted relative risk 1.31, 99% confidence interval
[CI] 1.26–1.36). Analyses of individual drug classes showed the risk of nursing home admission
was similar, or lower, for inappropriate drugs versus other drugs of the same class. For example,
the relative risk of nursing home admission was 2.34 (99% CI 2.20–2.47) for inappropriate
narcotics and 2.68 (99% CI 2.55–2.82) for other narcotics, compared with no narcotic use.
Conclusion—Inappropriate drug use was associated with increased risk of nursing home
transition, but the increased risk may be explained by underlying patient conditions for which the
drugs were prescribed rather than the inappropriate drug.
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Admission to a nursing home is a sentinel event for older adults. It marks a major transition
from community-based living, often in the comfort of one's home, to an institutionalized
setting. Older individuals with functional and cognitive deficits have the greatest likelihood
of nursing home admissions.1,2 Although much is known about risk factors for nursing
home admission, many of these factors cannot be intervened upon. One potentially
modifiable factor is a decline in health and function due to an adverse drug event.
Compared with their younger counterparts, older adults are at significantly higher risk for
medication-related adverse events. Explanations for this higher risk among elders include
increased incidence and prevalence of comorbid conditions; increased use of prescribed and
alternative medications; greater susceptibility to drug– disease, drug–nutrient, and drug–
drug interactions; psychosocial and cognitive changes that may affect treatment adherence;
lack of coordination among prescribers; and lack of pharmacology and therapeutics
knowledge specific to geriatrics.3–5 Together, these factors may lead to inappropriate
medication use by the patient, inappropriate prescribing by the health care professional, and
inadequate monitoring. Inappropriate medication use and subsequent adverse events are
potentially preventable risk factors for elders transitioning from independent living
situations to long-term care, acute care hospital and other dependent environments.
However, little is known about the relationship between inappropriate medication use and
transitions to nursing homes.
Inappropriate medication use has been defined as the use of medications that should be
entirely avoided, medications that should be avoided at excessive dosages, and medications
that should not be used for excessive durations of treatment.6,7 Inappropriate medication use
has been measured using various approaches, such as drug utilization review,8–16 the
Medication Appropriateness Index17 and “drugs-to-avoid” criteria (eg, Beers' criteria).6,7,18
Of all the various criteria used to evaluate medication prescribing appropriateness, the most
widely used and accepted are the criteria developed by Beers.6,7,18 One advantage of the
Beers criteria is that they can be applied to populations using pharmacy claims and that they
require minimal clinical information. A disadvantage is that when used alone, Beers criteria
do not include the richness of information obtained from a medical record review.
There is an informative body of descriptive analyses on medication use in the elderly,
including prevalence of potentially inappropriate use. Specifically, much research has been
published on the extent of use of medications that should be entirely avoided in the
elderly.6,7,18–24 However, there is a lack of empirical studies of the relationship between
medication use factors and health outcomes.8,25–27 Thus, the objective of this study was to
estimate the association between inappropriate medication use and transitions from
independent to dependent care environments in older adults.
Methods
Data Source
The MarketScan Medicare Supplemental and Coordination of Benefits database was used
for the analyses. The database, produced by Thomson Medstat, contains information on a
convenience sample of privately insured individuals who are covered by employer-
sponsored Medicare supplemental benefit plans. Employers who contribute data to the
MarketScan database are generally self-insured. The longitudinal database links medical and
prescription drug administrative claims with person-level enrollment data.
Study Design
A retrospective cohort design was used. A cohort was assembled from 3 years (2000, 2001,
and 2002) of MarketScan data. Subjects were included in the analysis if they were age 65
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years and older and had 1 year of eligibility with no nursing home admissions; the first full
year of eligibility was the subject's baseline period. Because the exposure variable is based
on measuring prescription drug use, subjects without any prescription coverage were
excluded, and periods of observation without supplemental insurance and prescription drug
coverage were excluded. Subjects were followed until their first admission to a nursing
home after the 1-year baseline period, loss to follow-up or the end of the study period
(December 31, 2002). Thus, subjects were followed for a maximum of 24 months after their
1-year baseline period.
Measures
The outcome in this study was transition to a nursing home, which was measured during
each person-month of observation. The exposure of interest was drug use. Because drug use
can vary over the course of time, drug use variables were treated as time-dependent.
Measures for potentially inappropriate medication use were developed at the person-month
level. Potentially inappropriate medications were defined using criteria developed by Beers
and others6,7,18 using the most recently updated list of potentially inappropriate
medications.18 A variable was created for each person, for each month, for each potentially
inappropriate drug (eg, chlordiazepoxide) and for each drug category (eg, long-acting
benzodiazepines), which resulted in 74 potentially inappropriate drugs, and 21 potentially
inappropriate drug classes. A variable was also created reflecting the monthly count of any
potentially inappropriate drug for each person.
In addition to person-month counts of potentially inappropriate drugs, additional person-
month drug use variables were created: a variable reflecting the count of any prescription
drug and a variable for the count of any prescription that was not considered inappropriate
(ie, “other drugs”). Thus, the sum of the monthly inappropriate drug and other drug counts
equaled the total monthly prescription drug count. Finally, to have clinically meaningful
reflections of drug prescribing prior to nursing home admission or censorship (ie, loss to
follow-up or December 2002, whichever occurred first), the monthly measures of drug use
were used to calculate rolling counts of previous 3-month use at each month, which were
used in the models as the prior drug use variables.
Other measures included in the analysis were potential confounders of the association
between medication use and nursing home transition, including sociodemographic variables,
comorbidities and previous hospitalization. Dementia and depression were included because
they have been found to be associated with nursing home admission.28 Additionally, as a
measure of overall health status and comorbidity, the Diagnostic Cost Group/Hierarchical
Coexisting Condition (DCG/HCC) tool, a risk adjuster derived from Medicare claims, was
used to control for comorbidities during the baseline period. The DCG/HCC is the basis for
the “selected significant disease model” that the Centers for Medicare and Medicaid
Services have used to set capitation rates for Medicare HMOs since January 2004.29 This
model created indicators for the presence of 189 medical conditions. The risk adjuster then
applies previously calibrated weights to approximately 100 of these conditions to create a
summary score of the patient's expected Medicare expenditure under Parts A and B for the
following year. The application of the DCG/HCC model used the 12 months of baseline
inpatient and outpatient claims to create a predicted value for services in the immediate
postadmission year for each study subject. As an additional measure of health status, a
variable indicating employment status (actively working full or part time versus retired) was
included. Previous hospital utilization is also a strong predictor of future nursing home use,
so a variable expressing the number of hospital admissions during the 1 year baseline period
was created for use in the modelbuilding strategy.
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A continuous time proportional hazards model for interval-censored data was used to
estimate the association between nursing home transition and inappropriate drug use.
Selection of the model was based on several considerations. First, since data on each
individual may be incomplete (eg, periods of insurance ineligibility), survival analysis was
used to allow for inclusion of all available data with censoring of subjects lacking complete
data. A second data issue is the use of interval-censored data. This means that the outcome is
known to have occurred during a particular interval of time, in this case, the month. The Cox
proportional hazards model does not adequately handle interval-censored data. A maximum
likelihood method with a complementary log-log link for the linear model was used which
allows for time-varying explanatory variables and also efficiently handles large numbers of
ties and large datasets.30,31 The regression coefficient estimates can be interpreted as log-
relative hazards, such that the exponentiated coefficients have a relative risk interpretation,
similar to the Cox model coefficients. This method requires that each individual have only 1
event. Thus, to use the patient as the unit of analysis and to maintain independence of
observations, the first admission was modeled. Using this method, a multivariable model
was developed to assess the association between any inappropriate drug use and nursing
home admission. In addition, separate models were developed to assess the association
between each inappropriate drug class and nursing home admission. Alpha was set at P =
0.01 for determination of level of statistical significance. Relative risks (RR) and 99%
confidence intervals (CI) are reported.
Analyses comparing use of inappropriate drugs to use of no inappropriate drugs do not
answer whether it is the inappropriateness of the drug that increases the risk of nursing home
transition, or whether it is the use of a drug in that class (regardless of appropriateness of the
specific drug) or the reason for which the drug was prescribed, that accounts for the
increased risk of nursing home transition. To assess whether effects are due to confounding
by indication, additional analyses were undertaken for those drug classes that had the largest
effect sizes and that had other drugs available which had not been declared “inappropriate”
for use in the elderly. These analyses compared class-specific inappropriate drug use to
class-specific “other” drug use and to no use of drugs in the specific drug class with respect
to the risk of nursing home transition. As in previous analyses, the drug use period is time-
dependent and is defined as use in the previous 3 months.
Power analysis and sample size estimation were performed prior to initiating the study.
Assuming an alpha of 0.01 and beta of 0.1, annual incidence of nursing home admission
among those without inappropriate medication use as low as 2% and the prevalence of
inappropriate medication use as low as 5%, a sample size of 450,000 provided enough
power to detect a relative risk as low as 1.21.
Results
During the years 2000 through 2002, there were 1,243,504 subjects enrolled in MarketScan
Medicare Supplemental and Coordination of Benefits database. A cohort of 487,383 subjects
was available for analysis after applying inclusion and exclusion criteria (Fig. 1).
On average, each subject had 20 months of follow-up during the study period, with a range
of 1 to 24 months, accounting for a total of 9,384,444 person-months of observation. More
than 50% of the subjects had the maximum 24 months of follow-up during the study period.
Table 1 provides descriptive information on baseline covariates. The mean age was 73.8
years; 55.5% were women, and more than 75% lived in a standard metropolitan statistical
area. Almost one-half of the subjects had a comprehensive Medicare supplemental insurance
plan (vs. a preferred provider organization or point-of-service plan with or without
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capitation) and more than 95% were retired. Nearly 3% of the subjects had a diagnosis of
dementia, and 2.1% had a depression diagnosis. Median predicted Medicare spending was
$2928 and the range was $1212 to $57,918.
Fewer than 14% of the subjects had no prescription drugs during the baseline year. Annual
prevalence of potentially inappropriate drugs, defined as 1 or more prescriptions for any of
the 74 potentially inappropriate drugs during the baseline year, was 41.9%. Annual baseline
prevalences for individual classes of potentially inappropriate drugs ranged from 0% to
14.0%. Hormones, which include systemic estrogens and methyltestosterone, were the most
prevalent of the inappropriate drug classes, with 14.0% of the cohort having a prescription.
Annual prevalence of inappropriate drug use, excluding hormones, was 35.9%. Use of
potentially inappropriate analgesics (propoxyphene, meperidine and pentazocine) (10.0%)
also was high.
Of the 487,383 subjects in the cohort, 22,042 (4.5%) experienced a nursing home transition
during the 24-month study period. The 1-year cumulative incidence was 26.7 transitions per
1000 subjects.
Table 2 shows the unadjusted and adjusted risk ratios for nursing home admission for each
of the covariates, including the exposure of interest, any inappropriate drug. All variables
remained significant after adjustment, although the effects were attenuated. A 31% increase
in risk of transition was identified among subjects with any inappropriate drug use during
the previous 3 months, as compared with subjects without any inappropriate drugs (Table 2,
adjusted RR 1.31, 99% CI 1.26–1.36). Use of any other drug (ie, drugs not considered
inappropriate) was also associated with nursing home transition.
Table 3 displays unadjusted and adjusted relative risks of nursing home transition for each
class of inappropriate drugs). In the adjusted models for individual drug classes, hormones
were the only drug class with a significant protective effect on nursing home transition
(adjusted RR 0.74, 99% CI 0.68–0.80). Antipsychotics, antiemetics and analgesics exhibited
the strongest effect, with relative risks ranging from 1.97 to 2.03.
Because of the controversy surrounding the risks and benefits of hormone replacement
therapy in postmenopausal women and of the observed protective effect on nursing home
transition, additional analyses were performed excluding hormones as a potentially
inappropriate drug. The use of potentially inappropriate drugs, excluding hormones,
remained a significant risk factor for nursing home transition (adjusted RR 1.45, 99% CI
1.40–1.51).
To further explore the association of potentially inappropriate drug use and nursing home
transition, additional analyses were undertaken for the 3 classes of drugs with the largest
effect sizes (ie, narcotic analgesics, antiemetics and antipsychotics). The adjusted relative
risks are shown in Table 4. For narcotic analgesics and antiemetics, the risk of nursing home
transition was similar for inappropriate drugs and other drugs. Inappropriate narcotic
analgesics included propoxyphene, meperidine and pentazocine. All other narcotic
analgesics were considered to be alternatives to the inappropriate narcotic analgesics. Both
inappropriate and alternative narcotic analgesic drug use, compared with no narcotic
analgesic drug use, were associated with about a 2.5-fold increased risk of nursing home
transition. The relative risk of other narcotic analgesics was statistically significantly higher
than inappropriate narcotic analgesics (RR 1.15, 99% CI 1.07–1.23).
Similarly, for antiemetic drug use each person-month was categorized with regard to
antiemetic use during the previous 3 months: inappropriate antiemetics, other antiemetics
and no antiemetics, with this last group as the reference category. There was only 1
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antiemetic, trimethobenzamide, which was considered inappropriate. Other antiemetics
included dimenhydrinate, dolasetron, dronabinol, granisetron, meclizine, metoclopramide,
ondansetron, prochlorperazine and triethylperazine. Both inappropriate and other antiemetic
use, compared with no antiemetic use, were associated with about a 2-fold increased risk of
nursing home transition, with no statistically significant difference between inappropriate
and other antiemetics.
The risk associated with other antipsychotic drugs was greater than that of inappropriate
antipsychotic drugs (Table 4). Two antipsychotics, mesoridazine and thioridazine, were
considered to be potentially inappropriate in the elderly. Other antipsychotics included:
aripiprazole, chlorpromazine, clozapine, droperidol, fluphenazine, haloperidol, loxapine,
molindone, olanzapine, perphenazine, pimozide, prochlorperazine, quetiapine, risperidone,
thiothixene, trifluoperazine, and ziprasidone. Other antipsychotic use was associated with a
more than 4-fold increase in the risk of nursing home transition (adjusted RR 4.25, 99% CI
3.98–4.54) whereas inappropriate antipsychotics had only a 2.5-fold increase in risk
(adjusted RR 2.50, 99% CI 1.62–3.87). The risk of nursing home admission was statistically
significantly greater for other antipsychotics compared with inappropriate antipsychotics
(adjusted RR 1.70, 99% CI 1.09–2.64).
Discussion
In a large, noninstitutionalized population of Medicare beneficiaries with employer-
sponsored supplemental health insurance, use of medications deemed to be inappropriate in
the elderly was associated with a 31% increase in risk of nursing home transition. The
relative risk varied by the inappropriate medication drug class, with relative risks as high as
2.0 for inappropriate analgesics, antiemetics and antipsychotics. This effect size is similar to
what Lau and colleagues found when they examined the relative odds of hospitalization
associated with inappropriate medication use among nursing home residents. They reported
a 27% increase in odds for hospitalization among residents who received inappropriate drug
therapy, compared with those who did not receive inappropriate drug therapy in either the
same month or for 2 consecutive months prior to the hospitalization.26
However, analyses of individual drug classes of inappropriate medications suggest that the
association is confounded by indication, a classic issue in observational studies of drug
effects.32 It was consistently found that the risk of nursing home transition was similar for
inappropriate drugs and “other” drugs of the same drug class. Therefore, it may not be the
“inappropriateness” of the drug that increased the risk of nursing home transition, but rather
the indication for the drug itself (eg, pain and symptom control, or mental disorder). If the
association is not causal, then interventions to decrease use of these inappropriate
medications may not result in a decrease in incidence of nursing home transition. Hanlon
and colleagues also suggested that drugs-to-avoid lists such as Beers be “accepted with
caution.”8,27 Indeed, in a cohort of 3076 community-dwelling elderly, Fillenbaum, Hanlon
and colleagues failed to find a statistically significant association between inappropriate
drug use and nursing home admission.27 This may be attributed to their smaller sample size,
use of self-reported nursing home admission and drug use rather than administrative claims
data as in this study, and differences between their patient population and the MarketScan
cohort.
Hormone drug use appeared to have a protective effect on nursing home transition. This may
be the result of confounding by health-related factors; that is, healthier women, or women
with healthy lifestyles, may be more likely to take hormone replacement therapy than less
healthy women. However, the DCG/HCC as a comorbidity risk adjuster used in this study
has been shown to control effectively for comorbidity confounding.33,34 It is also possible
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that hormone drug use may not be considered inappropriate, and actually provides a benefit,
in some elderly women. When hormone drugs were excluded from the operational definition
of inappropriate drugs, the relative risk of nursing home transition was slightly higher than
when hormone drugs were included.
Incidence of nursing home transition in this community sample of Medicare beneficiaries
was low. One-year cumulative incidence was 2.67%. The low incidence is not surprising for
several reasons. First, the sample comprised community residents for at least 10 months, so
sicker, institutionalized elderly were excluded. Second, all individuals had private health
insurance in addition to Medicare. On average, their income, education, and health were
likely to be better than that of the general population of the same age. The low incidence
found in this study was consistent, however, with other findings in similar populations. In an
extensive review of the literature on outcomes in the elderly, Miller and Weissert estimated
the annual incidence of nursing home admission among nondisabled community elders to be
2.9%, with estimates ranging between 2.0% and 3.5%.35
Annual prevalence of inappropriate drug use during the baseline year was 41.9%, which is
higher than in other studies using similar criteria among community-dwelling
elderly.22,23,36,37 This is most likely explained by the way in which inappropriate drugs
were operationalized. To date, there are few published studies examining prevalence of
inappropriate medications using the most recently published Beers list.18 This list contains
25 additional drugs that should not be used in the elderly, of which 21 were included in this
study (drugs that depended upon dose, duration or diagnosis were not included in this
study). The addition of these inappropriate drugs may have accounted for the increased
prevalence. Indeed, prevalence of hormone use alone was nearly 14%. When hormones were
excluded from the operational definition of inappropriate drugs, the annual prevalence was
35.9%, which is still higher than in previously published reports. When all newly added
inappropriate drugs were excluded, the annual prevalence was 28.4%, which is closer to but
still somewhat higher than other published estimates, which range from 21% to 25%.22,36–38
Thus, it is possible that variation in the way inappropriate drug use was defined in this study
affected the estimate of prevalence of inappropriate drug use. An alternative explanation for
the higher inappropriate drug prevalence is that our study population has a higher use of
inappropriate drugs. However, the prevalence of selected highly prevalent drugs
(propoxyphene, amitriptyline and diazepam) was similar to that in other published
estimates.22,23,36,37
Although the absolute risk of nursing home transition was low, the high prevalence of
inappropriate medication use could have potentially important clinical and economic
implications, if the association between inappropriate medication use and nursing home
transition is indeed causal. With a relative risk of 1.31 and an inappropriate drug prevalence
of 41.9%, the attributable risk fraction in the population is 11.5%. However, it is only valid
to consider attributable risk if the association between inappropriate drug use and nursing
home transition is a causal one.
This study has several strengths. The large sample size provides robustness to the
conclusions, protecting against a Type 2 error. Since the outcome was a rare event, a large
sample size was necessary to detect small relative risks and to produce precise estimates.
Another strength of this study is the drug use measure, which was measured as a time-
dependent variable. This ensured that the drug exposure preceded the potential outcome and
was close enough in time to be plausibly related to the potential event. This study also
addressed confounding by indication by comparing the risk of nursing home admission
among inappropriate drug users to users of other drugs of the same drug class.
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Selection bias is a potential concern in this study. In a cohort study, selection bias can be
viewed as unobserved confounding; not all potential confounders can be measured in this
database. These unobserved variables may be correlated with nursing home admission and
inappropriate drug use, thereby acting as confounders.39 Although the MarketScan database
is rich with information about nursing home utilization, medication utilization, and
insurance coverage information, it lacks important clinical measures of cognitive and
functional status (eg, mini-mental examination, activities of daily living). In addition, it does
not have data on race/ethnicity, which may be an important confounder, since white race and
non-Hispanic ethnicity have been positively associated with nursing home transition28 and,
in some studies, white race has been positively associated with inappropriate medication
use.23
Information bias is another threat to the internal validity of this study. In this study,
prescription drug claims were used as a proxy for drug exposure. Claims databases such as
MarketScan provide an efficient way to measure drug exposure, and an acceptable, reliable
resource for epidemiological and other health research,40,41 and may even be considered a
strength of this study, since use of prescription claims reduces potential recall bias that may
arise from collection of self-report data. However, misclassification of drug exposure may
occur because of medication noncompliance, or incomplete or missing data.41 For example,
prescription claims do not include over-the-counter drug utilization, unless there was a
prescription claim generated for coverage and payment of the over-the-counter drug, which
is unusual.42 Because there is no reason to believe that misclassification of drug exposure
would be different for those with and without nursing home transitions, bias would be likely
towards the null.43
Finally there is questionable generalizability of results from MarketScan samples.44 Since
MarketScan is a convenience sample of commercially insured elders with Medicare (and in
this study, the sample was limited to those with prescription drug coverage), the population
from which the MarketScan data are drawn may not be representative of all commercially
insured, nor is it representative of all elderly in the United States. However, based on age,
gender, and urban/rural residence, the study sample appears to be fairly representative of
Medicare beneficiaries with employer-sponsored private insurance.
Conclusion
Inappropriate drug use was associated with an increased risk of nursing home transition, but
the increased risk may be explained by underlying patient conditions for which the drugs
were prescribed rather than the inappropriate drug, because findings at the drug class level
suggest that the association may be confounded by indication. Interventions to decrease
inappropriate drug use continue to be conducted without a clear understanding of what
constitutes drug therapy inappropriateness.45,46 There is a tremendous need for additional
research on measurement of inappropriate drug therapy that is more comprehensive than
simply a list of drugs that should not be used. Thus, until there are measures with improved
predictive validity, clinicians and policy makers should be cautious before investing in
interventions to decrease potentially inappropriate drug use.
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Table 1
Baseline Characteristics of the Study Cohort (n = 487,383)
Characteristic n Percent
Age (years)
 65–69 158,630 32.5%
 70–74 127,482 26.2%
 75–79 101,254 20.8%
 80–84 61,468 12.6%
 85+ 38,549 7.9%
Gender
 Male 216,964 44.5%
 Female 270,419 55.5%
Metropolitan statistical area
 No 111,583 22.9%
 Yes 375,800 77.1%
Geographic region
 Northeast 91,362 18.7%
 North Central 188,446 38.7%
 South 174,151 35.7%
 West 33,424 6.9%
Benefit plan type
 Comprehensive 224,136 46.0%
 PPO or POS without capitation 154,870 31.8%
 POS with capitation 108,377 22.2%
Employment status
 Actively working full or part time 14,914 3.1%
 Retiree/other 472,469 96.9%
Dementia diagnosis
 Yes 14,094 2.9%
 No 473,289 97.1%
Depression diagnosis
 Yes 10,200 2.1%
 No 477,183 97.9%
Predicted Medicare spending ($)
 ≤2000 142,187 29.2%
 2000s 106,778 21.9%
 3000s 78,274 16.1%
 4000s 46,848 9.6%
 5000s 30,600 6.3%
 6000s 21,029 4.3%
 7000s 14,664 3.0%
 ≥8000 47,003 9.6%













Zuckerman et al. Page 14
Characteristic n Percent
Previous hospitalizations (within the past year)
 None 421,929 86.6%
 1 55,292 11.3%
 ≥2 10,162 2.1%
Total prescriptions
 0 65,283 13.4%
 1–12 105,500 21.6%
 13–24 102,304 21.0%
 ≥25 214,296 44.0%
Prescriptions for potentially inappropriate drugs
 0 283,300 58.1%
 1–12 180,791 37.1%
 13–24 19,599 4.0%
 ≥25 3693 0.8%
Prescriptions for other drugs
 0 67,861 13.9%
 1–12 117,488 24.1%
 13–24 106,160 21.8%
 ≥25 195,874 40.2%
All characteristics were measured during the baseline year prior to the study period. PPO indicates Preferred Provider Organization; POS, Point-of-
Service.
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Table 2
Relative Risk (RR) of Nursing Home Admission by Drug Use and Baseline Characteristics
(n = 487,383 subjects; 9,384,444 person-months of observation)
Unadjusted Adjusted*
Variable RR 99% CI RR 99% CI
Prescriptions for potentially inappropriate drugs†
 None 1 referent 1 referent
 1 or more 1.45 1.39, 1.50 1.31 1.26, 1.36
Prescriptions for other drugs†
 None 1 referent 1 referent
 1–12 1.61 1.52, 1.70 1.32 1.24, 1.40
 13 or more 3.31 3.11, 3.52 1.67 1.57, 1.79
Age (years)
 65–69 1 referent 1 referent
 70–74 2.18 2.02, 2.35 1.78 1.65, 1.93
 75–79 4.43 4.12, 4.77 2.72 2.52, 2.94
 80–84 8.25 7.67, 8.86 4.43 4.10, 4.78
 85 or older 16.32 15.20, 17.52 7.72 7.14, 8.34
Gender
 Male 1 referent 1 referent
 Female 1.35 1.30, 1.41 1.27 1.22, 1.32
Metropolitan statistical area
 No 1 referent 1 referent
 Yes 1.25 1.20, 1.31 1.08 1.03, 1.13
Geographic region
 West 1 referent 1 referent
 Northeast 1.74 1.60, 1.87 1.55 1.43, 1.69
 North Central 1.29 1.19, 1.40 1.17 1.08, 1.27
 South 0.98 0.90, 1.06 0.97 0.89, 1.05
Benefit plan type
 PPO or POS without capitation 1 referent 1 referent
 Comprehensive 0.92 0.88, 0.95 0.91 0.86, 0.95
 POS with capitation 0.69 0.65, 0.72 0.81 0.77, 0.85
Employment status
 Retiree/other 1 referent 1 referent
 Actively working 0.22 0.17, 0.27 0.61 0.48, 0.77
Dementia diagnosis
 No 1 referent 1 referent
 Yes 5.32 5.04, 5.61 2.25 2.13, 2.38
Depression diagnosis
 No 1 referent 1 referent
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Unadjusted Adjusted*
Variable RR 99% CI RR 99% CI
 Yes 2.27 2.08, 2.47 1.25 1.14, 1.36
Predicted Medicare Spending ($)
 ≤2000 1 referent 1 referent
 2000s 3.32 3.03, 3.64 1.72 1.56, 1.90
 3000s 6.19 5.66, 6.76 2.27 2.06, 2.50
 4000s 8.05 7.34, 8.83 2.82 2.55, 3.12
 5000s 10.23 9.30, 11.24 3.32 2.99, 3.69
 6000s 11.93 10.80, 13.13 3.60 3.33, 4.02
 7000s 14.04 12.67, 15.57 4.07 3.64, 4.56
 ≥8000 18.73 17.19, 20.40 5.12 4.62, 5.66
Hospitalizations in the baseline year
 None 1 referent 1 referent
 1 2.27 2.18, 2.37 1.09 1.04, 1.15
 2 or more 3.89 3.61, 4.20 1.39 1.28, 1.50
*
Adjusted for all other variables in the table.
†
Drug use is based on prescriptions during the previous 3 months.
PPO indicates Preferred Provider Organization; POS, Point-of-Service.
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Table 3
Relative Risk (RR) of Nursing Home Admission by Potentially Inappropriate Drug Use
Therapeutic Classes (n = 487,383; 9,384,444 person-months of observation)
Unadjusted Adjusted†
Specific Drug Class of Inappropriate Drugs* RR 99% CI RR 99% CI
Antipsychotics 3.48 2.25, 5.39 2.03 1.31, 3.14
Antiemetics 3.12 2.29, 4.28 2.02 1.47, 2.77
Analgesics 2.78 2.63, 2.93 1.97 1.86, 2.09
Skeletal muscle relaxants 1.65 1.50, 1.82 1.52 1.38, 1.67
Antibiotics 2.32 2.04, 2.64 1.51 1.33, 1.72
Antiarrhythmics 2.75 2.48, 3.05 1.51 1.36, 1.67
Antidepressants 1.63 1.51, 1.76 1.33 1.23, 1.44
Antihistamines 1.53 1.41, 1.65 1.31 1.21, 1.42
Long-acting benzodiazepines 1.33 1.18, 1.49 1.14 1.02, 1.28
Nonsteroidal antiinflammatory agents 1.03 0.81, 1.31 1.10 0.87, 1.40
Vasodilators 2.05 0.77, 5.42 1.07 0.40, 2.83
Gastrointestinal antispasmodics 1.22 1.07, 1.39 1.06 0.93, 1.21
Amphetamines 0.67 0.34, 1.34 1.05 0.53, 2.09
Antiplatelet drugs 1.60 1.32, 1.95 1.04 0.86, 1.27
Antihypertensives 1.17 1.08, 1.28 1.02 0.94, 1.11
Histamine H2-receptor antagonists 0.94 0.72, 1.23 0.90 0.69, 1.17
Hypoglycemics 1.25 0.70, 2.22 0.82 0.46, 1.45
Thyroid drugs 0.99 0.78, 1.26 0.80 0.63, 1.02
Barbiturates 0.72 0.54, 0.98 0.79 0.58, 1.06
Hormones 0.56 0.52, 0.60 0.74 0.68, 0.80
Anxiolytics 0.88 0.49, 1.58 0.71 0.40, 1.29
*
Prescription use is based on prescriptions during the previous 3 months. Relative risks are used to compare the use of inappropriate drugs in the
drug class within the previous 3 months to no use of inappropriate drugs in the drug class within the previous 3 months.
†
Adjusted models are adjusted for age, gender, other drug use, metropolitan statistical area, region, insurance type, employment status, dementia,
depression, predicted Medicare spending, and previous hospitalizations.
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